Expert Interview
A Second Look: Discussing ORIC Pharmaceuticals's Rinzimetostat (ORIC-944), a PRC2 (EED) Inhibitor in Combination with Darolutamide for Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Ticker(s): ORICInstitution: Oncology Hematology Associates of West Broward
- Practicing hematology/oncology for the past 30 years and is currently the President at Oncology and Hematology Associates of West Broward
- Manages 100 patients with mCRPC
- Vice Chief of Staff at Northwest Medical Center and is a Staff Physician with privileges at University Hospital and Medical Center, Broward Health Coral Springs and Florida Medical Center.
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
